Botulinum toxin type A therapy for palmar and digital hyperhidrosis

Solomon, Barry A.; Hayman, R.W.

doi:10.1016/s0190-9622(00)90298-6

Cited by 43 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less than nanogram quantities of BT need to be delivered into a 1 cm 2 PFHH treatment site and the risk of toxicity from the pharmaceutical formulation of BT is low [28]. Therefore BT, in a liquid formulation, is an ideal candidate for MN-based delivery systems.…”

Section: Resultsmentioning

confidence: 99%

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin

Torrisi

Zarnitsyn

Prausnitz

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

Botulinum toxin A (BT) is used therapeutically for the treatment of primary focal hyperhidrosis, a chronic debilitating condition characterised by over-activity of the eccrine sweat glands. Systemic toxicity concerns require BT to be administered by local injection, which in the case of hyperhidrosis means multiple painful intradermal injections by a skilled clinician at 6-monthly intervals. This study investigates the potential of a liquid-loaded pocketed microneedle device to deliver botulinum toxin A into the human dermis with the aim of reducing patient pain, improving therapeutic targeting and simplifying the administration procedure. Initially, β-galactosidase was employed as a detectable model for BT to (i) visualise liquid loading of the microneedles, (ii) determine residence time of a liquid formulation on the device and (iii) quantify loaded doses. An array of five stainless steel pocketed microneedles was shown to possess sufficient capacity to deliver therapeutic doses of the potent BT protein. Microneedle-mediated intradermal delivery of β-galactosidase and formaldehyde-inactivated botulinum toxoid revealed effective deposition and subsequent diffusion within the dermis. This study is the first to characterise pocketed microneedle delivery of a liquid formulation into human skin and illustrates the potential of such systems for the cutaneous administration of potent proteins such as BT. A clinically appropriate microneedle delivery system for BT could have a significant impact in both the medical and cosmetic industries.

show abstract

Section: Resultsmentioning

confidence: 99%

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin

Torrisi

Zarnitsyn

Prausnitz

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…[2][3][4] In children and adolescents with palmar hyperhidrosis, Botox therapy has been shown to improve quality of life. 5 However, even when care is taken to place the drug subepidermally, it may affect the underlying musculature.…”

Section: Commentmentioning

confidence: 99%

“…This can cause self-limited, focal, subjective, or objective hand muscle weakness. 2,3,6 Texting refers to communication of an electronic message with a handheld communication device. This modern-day activity, usually achieved by using the thumbs to press buttons on a cellular telephone, requires the use of the intrinsic muscles of the hands.…”

Section: Commentmentioning

confidence: 99%

Writer’s Block: “Texting” Impairment as a Complication of Botulinum Toxin Type A Therapy for Palmar Hyperhidrosis

Lehman¹

2011

Arch Dermatol

View full text Add to dashboard Cite

“…111,[186][187][188] Thus, injection of minute amounts of neurotoxin into the muscle(s) to be paralyzed leads to a depression of the symptoms for a period of several months, and this is the best available treatment for dystonias, strabismus, 186 facial wrinkling, brow position, 187 as well as palmar and axillary hyperhidrosis.…”

Section: F Tetanus and Botulinum Neurotoxinsmentioning

confidence: 99%

Bacterial protease inhibitors

Supuran

Scozzafava

Clare

2002

Medicinal Research Reviews

149

120

View full text Add to dashboard Cite

Serine-, cysteine-, and metalloproteases are widely spread in many pathogenic bacteria, where they play critical functions related to colonization and evasion of host immune defenses, acquisition of nutrients for growth and proliferation, facilitation of dissemination, or tissue damage during infection. Since all the antibiotics used clinically at the moment share a common mechanism of action, acting as inhibitors of the bacterial cell wall biosynthesis or affecting protein synthesis on ribosomes, resistance to these pharmacological agents represents a serious medical problem, which might be resolved by using new generation of antibiotics, possessing a different mechanism of action. Bacterial protease inhibitors constitute an interesting such possibility, due to the fact that many specific as well as ubiquitous proteases have recently been characterized in some detail in both gram-positive as well as gram-negative pathogens. Few potent, specific inhibitors for such bacterial proteases have been reported at this moment except for some signal peptidase, clostripain, Clostridium histolyticum collagenase, botulinum neurotoxin, and tetanus neurotoxin inhibitors. No inhibitors of the critically important and ubiquitous AAA proteases, degP or sortase have been reported, although such compounds would presumably constitute a new class of highly effective antibiotics. This review presents the state of the art in the design of such enzyme inhibitors with potential therapeutic applications, as well as recent advances in the use of some of these proteases in therapy.

show abstract

Botulinum toxin type A therapy for palmar and digital hyperhidrosis

Abstract: Botulinum toxin provides a safe and efficacious alternative in the treatment of recalcitrant palmar and digital hyperhidrosis.

Cited by 43 publications

References 16 publications

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin

Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin

Writer’s Block: “Texting” Impairment as a Complication of Botulinum Toxin Type A Therapy for Palmar Hyperhidrosis

Bacterial protease inhibitors

Contact Info

Product

Resources

About